a possible increase in acute pancreatitis risk with gliptins (Januvia, etc) and GLP-1 agonists (Byetta, etc)

You'll hear more about a possible increase in acute pancreatitis risk with gliptins (Januvia, etc) and GLP-1 agonists (Byetta, etc).

New evidence suggests about one more case of acute pancreatitis for every 50 diabetes patients using these drugs for up to 2 years.

These incretin mimetics might cause inflammation that could lead to acute pancreatitis...and possibly pancreatic cancer.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote